COL4A3 and chronic kidney disease: In summary, in the Col4α3 knockout murine model of CKD, we observed that treatment with 1% FC—a lower dose than previously reported—decreased serum phosphate concentrations, increased iron parameters, substantially reduced circulating FGF23 levels, decreased markers of systemic and kidney inflammation, improved kidney function, and decreased kidney fibrosis.